Summary

Asia-Pacific liver fibrosis treatment market is expected to reach USD 9.93 billion by 2032 from USD 3.77 billion in 2024, growing at a substantial CAGR of 12.9% in the forecast period of 2025 to 2032.

Market Segmentation:
Asia-Pacific Liver Fibrosis Treatment Market, By Treatment Type (Medication and Surgery/Therapy), Stages ( F2, F1, F3, and F4), Indication (Non-Alcoholic Steatohepatitis (NASH), Hepatitis B & C-Induced Fibrosis, Alcoholic Liver Disease (ALD), Autoimmune Liver Diseases, Genetic Disorders, and Others), Gender(Male and Female), End User (Hospitals, Specialty Clinics, Clinics, Ambulatory and Research Centers, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (China, Japan, India, Australia, South Korea, New Zealand, Singapore, Thailand, Philippines, Malaysia, Indonesia, Vietnam, Taiwan, and Rest of Asia-Pacific) - Industry Trends & Forecast To 2032
Overview of Asia-Pacific Liver Fibrosis Treatment Market Dynamics:

Driver

• Increasing Prevalence of Liver Diseases
Restraint

• Limited Awareness of Liver Diseases
Opportunity

• Progress in Pipeline Products for Liver Fibrosis Treatment
Market Players:

The key market players operating in the Asia-Pacific liver fibrosis treatment market are listed below:

• Gilead Sciences, Inc.
• AbbVie Inc.
• Merck & Co., Inc.
• Novartis AG
• Intercept Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd
• Abbott
• La Renon Healthcare Pvt. Ltd.
• GENFIT SA
• Madrigal Pharmaceuticals
• Aligos Therapeutics
• Pfizer Inc.
• Enanta Pharmaceuticals, Inc.
• Bristol-Myers Squibb Company
• Vertex Pharmaceuticals Incorporated
• Takeda Pharmaceutical Company Limited
• Hepion Pharmaceuticals
• Echosens
• Galectin Therapeutics, Inc.
• Conatus Pharmaceuticals
• Tvardi Therapeutics
• Viking Therapeutics
• Calliditas Therapeutics AB
• Novomedix
• Galecto Biotech
• Pilant Therapeutics, Inc.
• Sagimet Biosciences
• Gyre Therapeutics, Inc.
• Akero Therapeutics, Inc.
• CureVac SE
• Novo Nordisk A/S
• Ipsen Pharma
• AdAlta Limited
• Alentis Therapeutics AG

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 130
1.1 OBJECTIVES OF THE STUDY 130
1.2 MARKET DEFINITION 130
1.3 OVERVIEW OF THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET 130
1.4 CURRENCY AND PRICING 132
1.5 LIMITATIONS 132
1.6 MARKETS COVERED 133
2 MARKET SEGMENTATION 137
2.1 MARKETS COVERED 137
2.2 GEOGRAPHICAL SCOPE 138
2.3 YEARS CONSIDERED FOR THE STUDY 139
2.4 DBMR TRIPOD DATA VALIDATION MODEL 140
2.5 MULTIVARIATE MODELLING 143
2.6 TREATMENT TYPE LIFELINE CURVE 144
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 145
2.8 DBMR MARKET POSITION GRID 146
2.9 MARKET END USER COVERAGE GRID 147
2.10 VENDOR SHARE ANALYSIS 148
2.11 SECONDARY SOURCES 149
2.12 ASSUMPTIONS 149
3 EXECUTIVE SUMMARY 150
4 PREMIUM INSIGHTS 153
4.1 PESTAL ANALYSIS 157
4.2 PORTERS FIVE FORCES ANALYSIS 158
4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY 159
4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY 160
4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY 162
4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY 163
4.3 EPIDEMIOLOGY 165
4.3.1 INCIDENCE OF ALL BY GENDER 165
4.3.2 TREATMENT RATE 165
4.3.3 TREATMENT RATE 166
4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 166
4.3.5 PATIENT TREATMENT SUCCESS RATES 167
4.4 MARKETED DRUG ANALYSIS 168
4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES 173
4.5.1 PATIENT FLOW DIAGRAM 173
4.5.2 KEY PRICING STRATEGIES 174
4.5.3 KEY PATIENT ENROLLMENT STRATEGIES 176
5 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: REGULATIONS 178
6 MARKET OVERVIEW 181
6.1 DRIVERS 183
6.1.1 INCREASING PREVALENCE OF LIVER DISEASES 183
6.1.2 RISING CONSUMPTION OF ALCOHOL 183
6.1.3 RISING LIVER TRANSPLANTATION RATES 184
6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH 185
6.2 RESTRAINTS 186
6.2.1 LIMITED AWARENESS OF LIVER DISEASES 186
6.2.2 REGULATORY CHALLENGES 186
6.3 OPPORTUNITIES 188
6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT 188
6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT 188
6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS 189
6.4 CHALLENGES 191
6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS 191
6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE 191
7 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE 193
7.1 OVERVIEW 194
7.2 MEDICATION 197
7.2.1 ANTIVIRAL AGENTS 199
7.2.1.1 VELPATASVIR/SOFOSBUVIR 199
7.2.1.2 TENOFOVIR 199
7.2.1.3 LEDIPASVIR/SOFOSBUVIR 199
7.2.1.4 SOFOSBUVIR 199
7.2.1.5 ENTECAVIR 199
7.2.2 ANTIFIBROTIC AGENTS 201
7.2.2.1 OBETICHOLIC ACID 201
7.2.2.2 TGF-Β INHIBITORS 201
7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS 201
7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS 201
7.2.2.5 OTHERS 201
7.2.3 ANTI-INFLAMMATORY DRUGS 203
7.2.3.1 CORTICOSTEROIDS 203
7.2.3.1.1 PREDNISONE 203
7.2.3.1.2 DEXAMETHASONE 203
7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS 204
7.2.3.2.1 INFLIXIMAB 204
7.2.3.2.2 ETANERCEPT 204
7.2.3.3 INTERLEUKIN (IL) INHIBITORS 205
7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB) 205
7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA) 205
7.2.4 IMMUNOSUPPRESSANTS 207
7.2.4.1 MYCOPHENOLATE MOFETIL 207
7.2.4.2 TACROLIMUS 207
7.2.4.3 CYCLOSPORINE 207
7.2.5 MARKETED DRUGS 208
7.2.5.1 VELPATASVIR/SOFOSBUVIR 208
7.2.5.2 TENOFOVIR 208
7.2.5.3 LEDIPASVIR/SOFOSBUVIR 208
7.2.5.4 OBETICHOLIC ACID (OCA) 209
7.2.5.5 SOFOSBUVIR 209
7.2.5.6 PIRFENIDONE 209
7.2.5.7 OTHERS 209
7.2.6 PIPELINE DRUGS 209
7.2.7 BRANDED DRUGS 210
7.2.7.1 EPCLUSA 210
7.2.7.2 VIREAD AND VEMLIDY 210
7.2.7.3 OCALIVA 210
7.2.7.4 HARVONI 211
7.2.7.5 SOVALDI 211
7.2.7.6 BARACLUDE 211
7.2.7.7 ACTOS 211
7.2.7.8 OTHERS 211
7.2.8 GENERIC DRUGS 211
7.2.9 ORAL 211
7.2.10 PARENTERAL 211
7.2.11 OTHERS 211
7.3 SURGERY/THERAPY 212
7.3.1 LIVER TRANSPLANTATION 213
7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT) 213
7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT) 213
7.3.4 SPLIT LIVER TRANSPLANTATION 213
7.3.5 DOMINO LIVER TRANSPLANT 213
7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES 214
7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL) 214
7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS) 214
7.3.6.3 LIVER ABLATION PROCEDURES 214
7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA) 214
7.3.6.3.2 MICROWAVE ABLATION (MWA) 214
7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION) 215
7.3.7.1 SEGMENTAL RESECTION 215
7.3.7.2 LOBECTOMY 215
7.3.7.3 WEDGE RESECTION 215
7.3.8 CELL-BASED THERAPY 216
7.3.8.1 STEM CELL THERAPY 216
7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS) 216
7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS) 216
7.3.8.2 GENE THERAPY 217
7.3.8.2.1 CRISPR-BASED LIVER REGENERATION 217
7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS 217
7.3.8.2.3 SIRNA-BASED THERAPIES 217
7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS 217
7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS 218
7.3.8.2.4.2 EMRICASAN 218
7.3.8.2.4.3 PENTOXIFYLLINE 218
7.3.8.2.4.4 LOSARTAN 218
7.3.8.2.4.5 METHYL FERULIC ACID 218
7.3.8.2.4.6 OTHERS 218
7.4 OTHERS 218
8 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES 219
8.1 OVERVIEW 220
8.2 F2 223
8.3 F1 224
8.4 F3 224
8.5 F4 225
9 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION 226
9.1 OVERVIEW 227
9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH) 230
9.3 HEPATITIS B & C-INDUCED FIBROSIS 231
9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS 231
9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS 231
9.4 ALCOHOLIC LIVER DISEASE (ALD) 232
9.5 AUTOIMMUNE LIVER DISEASES 233
9.5.1 AUTOIMMUNE HEPATITIS (AIH) 234
9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC) 234
9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC) 234
9.6 GENETIC DISORDERS 234
9.6.1 HEMOCHROMATOSIS 235
9.6.2 WILSON’S DISEASE 235
9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY 235
9.7 OTHERS 235
10 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER 236
10.1 OVERVIEW 237
10.2 MALE 240
10.2.1 40-55 YEARS 241
10.2.2 ABOVE 55 YEARS 241
10.2.3 BELOW 40 YEARS 241
10.3 FEMALE 242
10.3.1 ABOVE 55 YEARS 242
10.3.2 40-55 YEARS 242
10.3.3 BELOW 40 YEARS 242
11 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER 243
11.1 OVERVIEW 244
11.2 HOSPITALS 247
11.2.1 PUBLIC HOSPITALS 248
11.2.2 PRIVATE HOSPITALS 248
11.3 SPECIALTY CLINICS 248
11.3.1 HEPATOLOGY CLINICS 249
11.3.2 GASTROENTEROLOGY CLINICS 249
11.4 CLINICS 249
11.5 AMBULATORY AND RESEARCH CENTERS 250
11.6 OTHERS 251
12 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL 252
12.1 OVERVIEW 253
12.2 DIRECT TENDER 256
12.2.1 RETAIL SALES 257
12.2.1.1 HOSPITAL PHARMACY 257
12.2.1.2 RETAIL PHARMACY 257
12.2.1.3 ONLINE PHARMACY 257
13 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY REGION 258
13.1 OVERVIEW 259
13.2 ASIA-PACIFIC 262
13.2.1 CHINA 282
13.2.2 JAPAN 298
13.2.3 INDIA 314
13.2.4 SOUTH KOREA 330
13.2.5 AUSTRALIA 346
13.2.6 SINGAPORE 362
13.2.7 THAILAND 377
13.2.8 INDONESIA 392
13.2.9 MALAYSIA 407
13.2.10 TAIWAN 422
13.2.11 NEW ZEALAND 437
13.2.12 PHILIPPINES 452
13.2.13 VIETNAM 467
13.2.14 REST OF ASIA-PACIFIC 482
14 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE 483
14.1 COMPANY SHARE ANALYSIS: GLOBAL 483
15 SWOT ANALYSIS 484
16 COMPANY PROFILES 485
16.1 GILEAD SCIENCES, INC. 485
16.1.1 COMPANY SNAPSHOT 485
16.1.2 REVENUE ANALYSIS 486
16.1.3 COMPANY SHARE ANALYSIS 486
16.1.4 PRODUCT PORTFOLIO 487
16.1.5 RECENT DEVELOPMENT/NEWS 491
16.2 ABBVIE, INC. 493
16.2.1 COMPANY SNAPSHOT 493
16.2.2 REVENUE ANALYSIS 493
16.2.3 COMPANY SHARE ANALYSIS 494
16.2.4 PRODUCT PORTFOLIO 494
16.2.5 RECENT DEVELOPMENT 494
16.3 MERCK & CO, INC. 495
16.3.1 COMPANY SNAPSHOT 495
16.3.2 REVENUE ANALYSIS 496
16.3.3 COMPANY SHARE ANALYSIS 496
16.3.4 PRODUCT PORTFOLIO 496
16.3.5 RECENT DEVELOPMENT 496
16.4 NOVARTIS AG 497
16.4.1 COMPANY SNAPSHOTS 497
16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 498
16.4.3 COMPANY SHARE ANALYSIS 498
16.4.4 PRODUCT PORTFOLIO 498
16.4.5 PIPELINE PRODUCT PORTFOLIO 499
16.4.6 RECENT DEVELOPMENT 499
16.5 INTERCEPT PHARMACEUTICALS, INC. 500
16.5.1 COMPANY SNAPSHOTS 500
16.5.2 COMPANY SHARE ANALYSIS 500
16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 500
16.5.4 PRODUCT PORTFOLIO 501
16.5.5 PIPELINE PRODUCT PORTFOLIO 501
16.5.6 RECENT NEWS 502
16.6 ABBOTT 503
16.6.1 COMPANY SNAPSHOT 503
16.6.2 REVENUE ANALYSIS 503
16.6.3 PRODUCT PORTFOLIO 504
16.6.4 1.1.5 RECENT DEVELOPMENT 504
16.7 ALIGOS THERAPEUTICS 505
16.7.1 COMPANY SNAPSHOT 505
16.7.2 REVENUE ANALYSIS 505
16.7.3 PRODUCT PORTFOLIO 506
16.7.4 RECENT DEVELOPMENT 506
16.8 ALNICHE LIFE SCIENCES PVT. LTD. 508
16.8.1 COMPANY SNAPSHOT 508
16.8.2 PRODUCT PORTFOLIO 508
16.8.3 RECENT DEVELOPMENT 509
16.9 ALENTIS THERAPEUTICS AG 510
16.9.1 COMPANY SNAPSHOT 510
16.9.2 PIPELINE PRODUCT PORTFOLIO 510
16.9.3 RECENT DEVELOPMENT 510
16.10 ADALTA LIMITED 511
16.10.1 COMPANY SNAPSHOT 511
16.10.2 REVENUE ANALYSIS 511
16.10.3 PIPELINE PRODUCT PORTFOLIO 512
16.10.4 RECENT NEWS 512
16.11 AKERO THERAPEUTICS, INC. 513
16.11.1 COMPANY SNAPSHOT 513
16.11.2 REVENUE ANALYSIS 513
16.11.3 PIPELINE PRODUCT PORTFOLIO 513
16.11.4 RECENT DEVELOPMENT 514
16.12 BRISTOL-MYERS SQUIBB 515
16.12.1 COMPANY SNAPSHOT 515
16.12.2 REVENUE ANALYSIS 515
16.12.3 PRODUCT PORTFOLIO 516
16.12.4 RECENT DEVELOPMENT 516
16.13 CALLIDITAS THERAPEUTICS AB 517
16.13.1 COMPANY SNAPSHOT 517
16.13.2 PIPELINE PRODUCT PORTFOLIO 517
16.13.3 RECENT DEVELOPMENT 518
16.14 CUREVAC SE 519
16.14.1 COMPANY SNAPSHOT 519
16.14.2 REVENUE ANALYSIS 519
16.14.3 PRODUCT PORTFOLIO 520
16.14.4 RECENT DEVELOPMENT 520
16.15 CONATUSPHARMA 521
16.15.1 COMPANY SNAPSHOT 521
16.15.2 PRODUCT PORTFOLIO 521
16.15.3 RECENT DEVELOPMENT/NEWS 521
16.16 ENANTA PHARMACEUTICALS, INC. 522
16.16.1 COMPANY SNAPSHOT 522
16.16.2 REVENUE ANALYSIS 522
16.16.3 PRODUCT PORTFOLIO 523
16.16.4 RECENT DEVELOPMENT 523
16.17 ECHOSENS 524
16.17.1 COMPANY SNAPSHOT 524
16.17.2 PRODUCT PORTFOLIO 524
16.17.3 RECENT DEVELOPMENT/NEWS 525
16.18 F. HOFFMANN-LA ROCHE LTD 527
16.18.1 COMPANY SNAPSHOT 527
16.18.2 REVENUE ANALYSIS 527
16.18.3 COMPANY SHARE ANALYSIS 528
16.18.4 PRODUCT PORTFOLIO 528
16.18.5 RECENT DEVELOPMENT 528
16.19 GALECTO BIOTECH 529
16.19.1 COMPANY SNAPSHOT 529
16.19.2 REVENUE ANALYSIS 529
16.19.3 PIPELINE PRODUCT PORTFOLIO 529
16.19.4 RECENT DEVELOPMENT/NEWS 529
16.20 GALECTIN THERAPEUTICS, INC. 531
16.20.1 COMPANY SNAPSHOTS 531
16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS 531
16.20.3 PIPELINE PRODUCT PORTFOLIO 531
16.20.4 RECENT DEVELOPMENT 532
16.21 GYRE THERAPEUTICS, INC. 534
16.21.1 COMPANY SNAPSHOT 534
16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 535
16.21.3 PRODUCT PORTFOLIO 535
16.21.4 RECENT DEVELOPMENT/NEWS 536
16.22 GENFIT SA 537
16.22.1 COMPANY SNAPSHOTS 537
16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 537
16.22.3 PIPELINE PRODUCT PORTFOLIO 538
16.22.4 RECENT DEVELOPMENT 538
16.23 HEPION PHARMACEUTICALS 540
16.23.1 COMPANY SNAPSHOT 540
16.23.2 REVENUE ANALYSIS 540
16.23.3 PIPELINE PORTFOLIO 540
16.23.4 RECENT DEVELOPMENT 540
16.24 IPSEN PHARMA 542
16.24.1 COMPANY SNAPSHOT 542
16.24.2 REVENUE ANALYSIS 542
16.24.3 PIPELINE PRODUCT PORTFOLIO 543
16.24.4 RECENT NEWS/DEVELOPMENTS 543
16.25 LA RENON HEALTHCARE PVT. LTD. 545
16.25.1 COMPANY SNAPSHOT 545
16.25.2 PRODUCT PORTFOLIO 545
16.25.3 RECENT DEVELOPMENT 547
16.26 MADRIGAL PHARMACEUTICALS 548
16.26.1 COMPANY SNAPSHOTS 548
16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS 548
16.26.3 PRODUCT PORTFOLIO 548
16.26.4 RECENT DEVELOPMENT 549
16.27 NOVO NORDISK A/S 550
16.27.1 COMPANY SNAPSHOT 550
16.27.2 REVENUE ANALYSIS 550
16.27.3 PIPELINE PRODUCT PORTFOLIO 551
16.27.4 RECENT DEVELOPMENT 551
16.28 NOVOMEDIX 552
16.28.1 COMPANY SNAPSHOT 552
16.28.2 PIPELINE PRODUCT PORTFOLIO 552
16.28.3 RECENT DEVELOPMENT 552
16.29 PILANT THERAPEUTICS, INC. 553
16.29.1 COMPANY SNAPSHOT 553
16.29.2 REVENUE ANALYSIS 553
16.29.3 PIPELINE PRODUCT PORTFOLIO 554
16.29.4 RECENT NEWS 554
16.30 PFIZER INC. 555
16.30.1 COMPANY SNAPSHOT 555
16.30.2 REVENUE ANALYSIS 555
16.30.3 PIPELINE PRODUCT PORTFOLIO 556
16.30.4 RECENT DEVELOPMENT/NEWS 556
16.31 SAGIMET BIOSCIENCES 557
16.31.1 COMPANY SNAPSHOTS 557
16.31.2 REVENUE ANALYSIS 557
16.31.3 1.1.4 PRODUCT PORTFOLIO 557
16.31.4 RECENT DEVELOPMENT/NEWS 558
16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED 559
16.32.1 COMPANY SNAPSHOT 559
16.32.2 REVENUE ANALYSIS 560
16.32.3 PIPELINE PRODUCT PORTFOLIO 560
16.32.4 PRODUCT PORTFOLIO 561
16.32.5 RECENT DEVELOPMENT 562
16.33 TVARDI THERAPEUTICS 563
16.33.1 COMPANY SNAPSHOT 563
16.33.2 PIPELINE PRODUCT PORTFOLIO 563
16.33.3 RECENT DEVELOPMENT/NEWS 564
16.34 VERTEX PHARMACEUTICALS INCORPORATED 565
16.34.1 COMPANY SNAPSHOT 565
16.34.2 REVENUE ANALYSIS 565
16.34.3 PRODUCT PORTFOLIO 566
16.34.4 RECENT DEVELOPMENT 567
16.35 VIKING THERAPEUTICS 569
16.35.1 COMPANY SNAPSHOT 569
16.35.2 REVENUE ANALYSIS 569
16.35.3 PIPELINE PRODUCT PORTFOLIO 569
16.35.4 RECENT DEVELOPMENT 570
17 QUESTIONNAIRE 571
18 RELATED REPORTS